Dishman Carbogen Amcis Limited is a global pharmaceutical company that provides contract research, development, and manufacturing services for drug substances and specialty chemicals, supporting pharmaceutical and biotech clients from early-stage research to commercial production, with headquarters in Ahmedabad, India and operations across India, Europe, and Asia.
Key Management Personnel
Janmejay R. Vyas
Founder & Chairman
View all team
Financials
RevenueEBITDAPAT
Yearly
*All values are in cr
Company updates
News
Dishman Carbogen Amcis Ltd Hits Intraday High with 7.31% Surge on 3 Feb 2026•40 weeks ago
Dishman Carbogen Amcis Ltd recorded a robust intraday performance on 3 Feb 2026, surging 7.31% to touch a day’s high of Rs 233.5, significantly outperforming the broader market and its sector peers.
Dishman Carbogen Amcis allots ₹18 crore NCDs via private placement•21 weeks ago
Dishman Carbogen Amcis Limited has allotted 1,800 Senior, Secured, Rated, Listed, Transferable, Redeemable, Taxable Non-Convertible Debentures aggregating ₹18 crore through private placement. The Management Committee of the Board of Directors approved the allotment on June 9, 2026. The debentures carry a face value of ₹1,00,000 each and were issued at par for cash. The issuance follows the board's approval on March 18, 2026, to raise up to ₹150 crore via such instruments. The terms and conditions of the issue are detailed in the general information document dated December 30, 2025, and the key information document dated June 8, 2026.
Other disclosures
Documents
Key information document
Rating report
Disclaimer: Bond details and related information displayed on this page are sourced from Deridata and other available sources and are provided for informational purposes. While BondScanner may review or validate certain information before displaying it, the information may be subject to change and should not be relied upon as the sole basis for any investment decision. Investors are advised to independently verify critical information from the relevant offer documents and other official sources before investing.
Source: Derivium Tradition India Securities Pvt Ltd.